People: Delcath Systems Inc (DCTH.PH)

Summary

Name	Age	Since	Current Position
Harold Koplewicz	59	2007	Independent Chairman of the Board
Eamonn Hobbs	53	2009	President, Chief Executive Officer, Director
Graham Miao	47	2011	Chief Financial Officer, Executive Vice President
Peter Graham	45	2011	Executive Vice President, General Counsel and Global Human Resources
Krishna Kandarpa	61	2009	Executive Vice President - Research & Development, Chief Medical Officer
Harold Mapes	52	2011	Executive Vice President - Global Operations
David McDonald	51	2011	Executive Vice President - Business Development
John Purpura	50	2009	Executive Vice President - Regulatory Affairs and Quality Assurance
Jennifer Simpson	43	2013	Executive Vice President, Global Head - Business Operations
Barbra Keck	34	2009	Vice President, Controller
Laura Brege	55	2012	Director
Tasos Konidaris		2012	Director
Gabriel Leung	51	2011	Independent Director
Laura Philips	54	2007	Independent Director
Roger Stoll	69	2008	Independent Director
Douglas Watson	68	2010	Independent Director
Doug Sherk			IR Contact

» Insider Trading

Biographies

Name	Description
Harold Koplewicz	Mr. Harold S. Koplewicz, M.D., is Independent Chairman of the Board of Decalth Systems Inc., since February 1, 2007. He has been a Director of the company since September 2006. He is one of the nation’s child and adolescent psychiatrists, honored by the American Psychiatric Association, the American Society for Adolescent Psychiatry, and the American Academy of Child & Adolescent Psychiatry. In November 2009, he founded and became the President of the Child Mind Institute, the nation’s only independent nonprofit dedicated to transforming mental health care for the world’s children. In May 2006, he was appointed by then-New York Governor George Pataki to the position of Director of the Nathan S. Kline Institute for Psychiatric Research, where he was the third person to hold this position since the institution’s founding in 1952. He completed his tenure at NKI in January 2011. In 2007, Dr. Koplewicz became the first Vice Dean of External Affairs at the NYU Langone Medical Center. In the first year of his tenure, over $500 million in philanthropic support was raised for the Medical Center. Dr. Koplewicz founded the NYU Child Study Center in 1997 and served as its Director for twelve years. Under his leadership, the NYU Child Study Center made remarkable contributions to the field through clinical care, a robust research portfolio, and advocacy for child mental health. A graduate of Albert Einstein College of Medicine, Dr. Koplewicz completed his psychiatric residency at New York Hospital Westchester Division, a fellowship in Child Psychiatry at Columbia University’s College of Physicians and Surgeons, a NIMH Research Fellowship at the New York State Psychiatric Institute, and the Executive Program in Health Policy and Management at Harvard University’s School of Public Health. He has served as a member of the National Board of Medical Examiners and as a Commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System.
Eamonn Hobbs	Mr. Eamonn P. Hobbs is President, Chief Executive Officer, Director of Decalth Systems Inc., since October 2008. He was appointed President and Chief Executive Officer of Delcath in July 2009 and has been a director of Delcath since October 2008. . He has over 30 years of experience in the interventional radiology, interventional cardiology and gastroenterology medical device industries. From 1988 until 2009, Mr. Hobbs was President and CEO of AngioDynamics, Inc. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., a healthcare company focused on diagnostic technologies, where Mr. Hobbs served as Senior Vice-President since 1988. Before his involvement with these companies, Mr. Hobbs was the Director of Marketing and Product Development at NAMIC, Founder, President and CEO of Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated. He received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts, Lowell in 1980. In addition, since 2001, Mr. Hobbs has served as the only industry member of the strategic planning committee of the Society of Interventional Radiology, was elected to and served from 2002 to 2008 on the Board of Directors of the Society of Interventional Radiology Foundation (SIRF) and is currently Vice Chairman of the Medical Device Manufacturers Association (MDMA). Mr. Hobbs currently serves on the Board of Directors of Antares Pharma Co., a publicly traded company, and is a member of that Board’s audit committee, his service commenced in August 2009. Mr. Hobbs also served on the Board of Directors of AngioDynamics, Inc., a publicly traded company from 1988 to 2009. In 2010, Mr. Hobbs also joined the Board of Directors of Cappella Cardiovascular Innovations, Inc.
Graham Miao	Mr. Graham G. Miao, M.S., M.B.A., Ph.D., is Chief Financial Officer, Executive Vice President of Delcath Systems, Inc., effective September 26, 2011. Mr. Miao has financial and management experience in global business operations in the United States, Asia and Europe. He most recently served, since 2009, as Chief of Staff of the Global CFO Organization at The Dun & Bradstreet Corporation (NYSE: DNB). From 2007 to 2009, he served as Executive Vice President and Chief Financial Officer of Pagoda Pharmaceuticals Inc., a specialty pharmaceutical and medical device company; and, from 2004-2007, he served as Vice President, Strategic Planning and Financial Analysis, Global Flavors of Symrise Inc, a supplier of flavoring and fragrance products. Prior to joining Pagoda, Mr. Miao was Vice President of Strategic Planning & Financial Analysis at Symrise Inc., a German supplier of flavoring and fragrance products. In this role Mr. Miao served as division-CFO responsible for driving profitable growth of a $700 million business line. Mr. Miao was also Senior Director for Global Primary Care and Global Medical Affairs at Schering-Plough Corporation, serving as the division-CFO for the company’s $3 billion primary care pharmaceuticals franchise. Prior to his time at Schering-Plough, Mr. Miao was at Pharmacia Corporation, serving as Director-Head of Finance for Pharmacia’s $1.3 billion Global Oncology franchise. In this role, he reported operationally to Gabriel Leung, then Head of Global Oncology franchise for Pharmacia and current member of the Delcath Board of Directors. Earlier in his career, Mr. Miao worked as a biotechnology analyst at J.P. Morgan and Company. Mr. Miao earned a Ph.D. in Biological Sciences and an M.B.A. from Columbia University, an M.S. in molecular biology from Arizona State University, and a B.S. in biochemistry from Fudan University in Shanghai, China.
Peter Graham	Mr. Peter J. Graham is Executive Vice President, General Counsel and Global Human Resources of Delcath Systems, Inc. Mr. Graham joined Delcath in April 2010 and has been Executive Vice President, General Counsel and Global Human Resources since May 2011. From April 2010 until May 2011, he served as Executive Vice President, General Counsel. Prior to joining Delcath, he was Vice President, General Counsel and a member of the Executive Committee of ACIST Medical Systems, Inc. from April 2008 to April 2010. Prior to 2008, Mr. Graham spent 11 years at E-Z-EM, Inc. holding various senior level management positions including Senior Vice President, Chief Legal Officer, Global Human Resources and Secretary from 2005 to 2008 and Vice President, General Counsel and Secretary from 2001 until 2005. From 1997 until 2004 Mr. Graham also served as General Counsel and Secretary for AngioDynamics, Inc. then a wholly owned subsidiary of E-Z-EM, Inc. Mr. Graham earned his J.D. at Yeshiva University’s Benjamin N. Cardozo School of Law and his B.A. at the University of Wisconsin-Madison.
Krishna Kandarpa	Dr. Krishna Kandarpa, M.D, Ph.D., is Executive Vice President - Research & Development, Chief Medical Officer of Delcath Systems, Inc., effective October 20, 2009. Prior to joining Delcath, from 2002 to 2009, he was a tenured Professor and former Chair of the Department of Radiology at the University of Massachusetts Medical School (UMMS) and Radiologist-in-Chief at the University of Massachusetts Memorial Medical Center. Before joining the University of Massachusetts in 2002, he was at the Weill Medical College of Cornell University, where he was a Professor of Radiology and Chief of Service and Director of the Division of Cardiovascular & Interventional Radiology at The New York Presbyterian Hospital (Cornell). He was also a faculty member at the Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology from 1987 to 1998. Before deciding to attend medical school at the University of Miami, Dr. Kandarpa was a Research and Development Engineer at Duracell International Laboratory for Physical Science. He earned a Ph.D. in Engineering Science & Mechanics from Penn State University and a B.S. in Aerospace & Mechanical Engineering from Washington University (St. Louis). Dr. Kandarpa is past-President (1997-2001) and past-Chair (2001-2002) of the Cardiovascular & Interventional Radiology Research and Education Foundation (CIRREF) of the Society of Interventional Radiology (SIR). He completed his final term on the Board of Directors of the Academy of Radiology Research in 2007. Dr. Kandarpa has authored over 50 original peer-reviewed scientific publications, including book chapters and solicited review articles, and is the author/editor of several specialized books, including The Handbook of Interventional Radiologic Procedures, and a textbook entitled Peripheral Vascular Interventions (2008). Dr. Kandarpa is listed in America’s Top Doctors.
Harold Mapes	Mr. Harold C. Mapes, Jr., is Executive Vice President, Global Operations of Decalth Systems Inc., May 3, 2011. Prior to joining Delcath, Mr. Mapes was Senior Vice President of Operations at AngioDynamics, Inc., where Mr. Mapes was responsible for global sourcing, inventory, engineering, production, distribution, and operations across four sites employing 300 workers. In his 18 years at AngioDynamics, he also held the positions of Vice President Operations, Director of Operations and Manufacturing Engineering, and Product Development Project Manager. In those roles, he coordinated the strategic corporate planning function, reduced manufacturing costs through implementation of lean manufacturing methods, and improved production performance by focusing on continuous improvement and compliance. Mr. Mapes has also held leadership positions in Operations at Mallinckrodt Medical, Inc. (now Merit Medical), National-Standard Co., and IBM’s Federal Systems Division. Mr. Mapes earned a BS in Mechanical Engineering from Trine University, Angola, Ind., and an MBA from the State University of New York at Albany.
David McDonald	Mr. David Alan McDonald is Executive Vice President - Business Development of Delcath Systems, Inc., effective September 26, 2011. Mr. McDonald previously served as Delcath’s Chief Financial Officer from September 2009 to September 2011. He was formerly the Senior Vice President of Business Development at AngioDynamics, Inc., where he led the company’s business development activities. Mr. McDonald founded Minneapolis-based Cornerstone Healthcare Advisors LLC in April 2005, which he led until joining AngioDynamics in July 2008. At Cornerstone he provided advisory and consulting services to emerging medical technology companies and their financial sponsors. Prior to 2005, Mr. McDonald was a Managing Director and leader of Medical Technology Investment Banking at RBC Capital Markets. Before his involvement with these companies, Mr. McDonald was a Senior Vice President and Equity Portfolio Manager at Investment Advisers, Inc. as well as a research analyst covering the healthcare industry for more than a dozen years. He received a Bachelor of Arts Degree in Economics from St. Olaf College in Northfield, Minnesota in 1982.
John Purpura	Mr. John Purpura is Executive Vice President - Regulatory Affairs and Quality Assurance of Delcath Systems, Inc effective November 16, 2009. Prior to joining Delcath, he was with E-Z-EM, Inc. as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008 and Head of Regulatory Affairs for North America and Latin America from 2008 to 2009. Prior to E-Z-EM, Inc., Mr. Purpura had an 11 year career with Sanofi-Aventis, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. From 1985 to 1995, he had various quality and regulatory management roles with Bolar Pharmaceuticals, Luitpold Pharmaceuticals and Eon Labs Manufacturing. He earned his MS in Management & Policy and B.S. degrees in Chemistry and Biology at the State University of New York at Stony Brook.
Jennifer Simpson	Dr. Jennifer Simpson, Ph.D., M.S.N., C.R.N.P., has been appointed as Executive Vice President, Global Head - Business Operations of Delcath Systems, Inc., effective April 8, 2013. From 2011 to 2012, Ms. Simpson served as the Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc. (a wholly- owned subsidiary of Eli Lilly and Company), where she was responsible for all product commercialization activities and launch preparation for one of the late stage assets. From 2009 to 2011, Ms. Simpson served as the Vice President, Product Champion and from 2008 to 2009 as the Associate Vice President, Product Champion for ImClone’s product Ramucirumab. From 2006 to 2008, Ms. Simpson served as Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech company that focuses on innovative solutions in immunology, oncology and nephrology. Earlier in her Career, Ms. Simpson spent over a decade as a hematology/oncology-nurse practitioner and educator. Ms. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.
Barbra Keck	Ms. Barbra Keck is Vice President, Controller of Decalth Systems Inc., since October 2009. She joined Delcath as Controller in January 2009 and promoted to Vice President in October 2009. Prior to joining Delcath, she was an audit assistant with Deloitte & Touche, LLP from August 2008 to December 2008. From June 2006 to August 2008, Ms. Keck was the Assistant to the Vice President and Dean of Baruch College, Zicklin School of Business, and from September 2005 to May 2006 she was the Donor Relations and Communications Manager for Young Audiences New York. From 2002 to 2005, Ms. Keck was the Manager, UD Arts Series at the University of Dayton, where she also served as the Manager, Arts and Cultural Events from 1999 to 2002. Between those positions, from 2002 to 2003, she was the Director of Teacher Programs at the Muse Machine. Ms. Keck served as the General Manager of Dayton Bach Society and the Manager of UD Arts Series from 1999 to 2002. She earned her MBA in Accountancy from Baruch College and Bachelor of Music in Music Education from the University of Dayton.
Laura Brege	Ms. Laura A. Brege has been appointed as Director of Delcath Systems, Inc., effective July 5, 2012. Ms. Brege served as Executive Vice President of Corporate Affairs at Onyx Pharmaceuticals, a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. During her six-year tenure at Onyx, Ms. Brege held a number of senior management positions, including Chief Operating Officer during which time she led the U.S. commercial team. The team launched Nexavar(R) (sorafenib), an oral drug in two indications, kidney cancer in 2006 and liver cancer in 2007. Ms. Brege also led the company's partnership with Bayer AG on the worldwide development and commercialization of Nexavar(R). Prior to joining Onyx, Ms. Brege held a number of positions, including General Partner of Red Rock Management, a venture capital firm, Senior Vice President and Chief Financial Officer of COR Therapeutics, a biotechnology company focused on cardiovascular disease, CFO of Flextronics, Inc, a global technology company and Treasurer of The Cooper Companies, a diversified medical products company. She currently serves on the boards of Acadia Pharmaceuticals and Pacira Pharmaceuticals, as well as the Foundation Board of Ohio University. Ms. Brege received her Master's in Business Administration from the University of Chicago and her undergraduate degrees in Economics and Political Science from Ohio University, Honors Tutorial College, where she graduated summa cum laude.
Tasos Konidaris	Mr. Tasos G. Konidaris has been appointed as Director of Delcath Systems, Inc., effective July 5, 2012. Mr. Konidaris serves as Senior Vice President and Chief Financial Officer at Ikaria Inc., a company focused on bringing therapeutics to critically ill patients. At the company, Mr. Konidaris leads the finance function, focusing on developing strategies to maximize profitable growth, return of capital to shareholders, and ensuring financial controls and compliance in support of long-term growth strategy. Prior to joining Ikaria Inc., Mr. Konidaris served in several senior positions at Dun & Bradstreet Corporation (D&B), including Senior Vice President and Chief Financial Officer, and Principal Accounting Officer. Previously, Mr. Konidaris held senior positions at a range of companies, including Group Vice President of the Global Pharmaceutical Group at Schering-Plough Corporation; Vice President of Finance for North America and Global Business Management at Pharmacia Corporation. Prior to his time at Pharmacia, Mr. Konidaris held senior finance management positions at several global pharmaceutical companies including Rhone-Poulenc Rorer, Novartis Corporation, and Bristol-Myers Squibb. Mr. Konidaris received his Master's in Business Administration from Drexel University. He received his Bachelor of Science with a dual major in mathematics and finance at Gwynedd Mercy College, where he graduated with honors.
Gabriel Leung	Mr. Gabriel Leung, M.Sc., is Independent Director of Delcath Systems Inc., since March 30, 2011. Mr. Leung has a more then 25 years veteran of the pharmaceutical and biotechnology industry. Mr. Leung is currently Vice Chairman of Novocure, Ltd., a medical device company pioneering the fourth modality of cancer treatment. Mr. Leung served as President of the Oncology Unit of OSI Pharmaceuticals Inc., from 2005 until mid-2009, and then as President, Pharmaceutical Business, overseeing the oncology and diabetes businesses until its acquisition in 2010; and, prior to his appointment as President, (OSI) Oncology, as its Executive Vice President and President, Oncology Business beginning in 2003. Prior to joining OSI Pharmaceuticals, Mr. Leung was Group Vice President of Global Prescription Business at Pharmacia Corporation where he was employed from February 1999 to April 2003 and was a member of the CEO’s Operating Committee from May 2001 to April 2003. He headed Pharmacia’s Global Oncology Franchise where his responsibilities included medical affairs, marketing and sales worldwide in over 80 countries. Mr. Leung also co-chaired the Oncology Development Committee, which oversaw all oncology research and development projects and portfolio strategies. Prior to his employment with Pharmacia, Mr. Leung was at Bristol-Myers Squibb Company where he led the growth of Taxol® and Paraplatin® into the then first and selling chemotherapeutic agents in the United States. Mr. Leung is a pharmacist and trained at the University of Texas at Austin where he earned his B.S. degree with High Honors. He attended graduate school at the University of Wisconsin-Madison where he earned his M.S. degree in Pharmacy, with concentration in pharmaceutical marketing.
Laura Philips	Dr. Laura A. Philips is Independent Director of Decalth Systems Inc., since May 24, 2007. Dr. Philips currently serves on the Boards of Directors of: Wellgen, Inc., where she serves on the audit committee; Boyce Thompson Research Institute, where she serves as vice chair, chairs the audit committee, and serves on the investment committees; and Americans for UNFPA where she is Treasurer, chairs the finance committee and serves on the executive committee. Wellgen Inc. is a privately held company developing nutraceutical products for health and wellness. Ms. Philips is also Chair Emeritus of the Board of Planned Parenthood of New York City. She served on the Board of Directors of China Yongxin Pharmaceuticals Inc., from March 2010-March 2011, where she served on the compensation committee and the audit committee. Dr. Philips is currently a consultant for early stage companies. From 2003 to 2006, she was Chief Operating Officer and Acting Chief Financial Officer of NexGenix Pharmaceuticals. Prior to that, she was Vice President, Program Management for the AMDeC Foundation. Dr. Philips worked at Corning Incorporated from 1997 to 2002, where she held several executive level positions including Program Director of the Fuel Cells Division and Director of Product Development for the Materials Division. From 1994 to 1996, Dr. Philips held various government positions in Washington, D.C., most recently in a Presidential appointment as Senior Policy Advisor to Secretary of Commerce Ronald Brown. Dr. Philips was on the faculty of Cornell University in the Department of Chemistry from 1987 to 1994 and was an NIH Post-Doctoral Fellow at the University of Chicago. She received a B.A. in Chemistry from Williams College, a Ph.D. in Physical Chemistry from the University of California Berkeley and an MBA with Distinction from Cornell University’s Johnson School of Management.
Roger Stoll	Dr. Roger G. Stoll, Ph.D., is Independent Director of Delcath Systems, Inc., since December 5, 2008. From 2002 to 2008, he served as Chief Executive Officer and President of Cortex Pharmaceuticals, Inc., a publicly traded company, where he was appointed Executive Chairman in August 2008. From 2001 to 2002, he was a consultant to several east coast venture capital firms and startup ventures. From 1998 to 2001, he was Executive Vice President of Fresenius Medical Care-North America, in charge of the dialysis products division and the diagnostic systems business units, which included hemodialysis machines and dialysis filters equipment. From 1991 to 1998, Dr. Stoll was Chief Executive of Ohmeda, a global in anesthesia pharmaceuticals and related operating room equipment and devices. He also served on the boards of directors of St. Jude Medical and the BOC Group, plc. From 1986 to 1991, Dr. Stoll held several executive management positions at Bayer, AG, including Executive Vice-President and General Manager for the worldwide Diagnostic Business Group. Prior to that, Dr. Stoll worked for American Hospital Supply Corp., where he rose from Director of Clinical Pharmacology to President of its American Critical Care Division. He began his pharmaceutical career at the Upjohn Company in 1972. Dr. Stoll obtained his B.S. in Pharmacy from Ferris State University, obtained a Ph.D. in Biopharmaceutics and Drug Metabolism at the University of Connecticut, and was a post-doctoral fellow for two years at the University of Michigan. Dr. Stoll also serves on the board of directors of Chelsea Therapeutics and School of Pharmacy Advisory Board of the University of Connecticut.
Douglas Watson	Mr. Douglas G. Watson is Independent Director of Delcath Systems, Inc., effective July 12, 2010. He became President and CEO of Novartis Corporation in 1997 when Ciba-Geigy and Sandoz merged. Mr. Watson elected to take early retirement from Novartis in 1999, when he founded Pittencrieff Glen Associates, an executive-level management consulting organization. Mr. Watson is currently the Chairman of the Board of OraSure Technologies Inc., and serves on the Boards of Directors for BioMimetic Therapeutics Inc., Dendreon Corporation, and Genta Inc. His prior board memberships include Novartis Corporation, Summit Bank Corporation, Engelhard Corporation and Javelin Pharmaceuticals Inc. Mr. Watson joined Geigy (UK) Ltd. in 1966 and held multiple positions at Geigy and Ciba-Geigy in UK, Switzerland and USA. Mr. Watson earned his Masters of Arts degree in Pure Mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants. Mr. Watson also serves on the Boards of OraSure Technologies, Inc. (OSUR: Nasdaq), BioMimetic Therapeutics, Inc. (BMTI: Nasdaq), and Dendreon Corporation (DNDN: Nasdaq) and previously served on the Boards of Engelhard Corporation (a former public company), Genta Inc. (GNTA: OTCBB) and Javelin Pharmaceuticals Inc. (a former public company).
Doug Sherk

Basic Compensation

Name	Fiscal Year Total
Harold Koplewicz	--
Eamonn Hobbs	1,336,040
Graham Miao	561,917
Peter Graham	567,157
Krishna Kandarpa	506,324
Harold Mapes	--
David McDonald	666,696
John Purpura	--
Jennifer Simpson	--
Barbra Keck	415,752
Laura Brege	--
Tasos Konidaris	--
Gabriel Leung	--
Laura Philips	--
Roger Stoll	--
Douglas Watson	--
Doug Sherk	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Harold Koplewicz	0	0
Eamonn Hobbs	0	0
Graham Miao	0	0
Peter Graham	0	0
Krishna Kandarpa	0	0
Harold Mapes	0	0
David McDonald	0	0
John Purpura	0	0
Jennifer Simpson	0	0
Barbra Keck	0	0
Laura Brege	0	0
Tasos Konidaris	0	0
Gabriel Leung	0	0
Laura Philips	0	0
Roger Stoll	0	0
Douglas Watson	0	0
Doug Sherk	0	0

Insider Trading

Name	Shares Traded	Price
PHILIPS LAURA A	33,000	$0.00
KONIDARIS ANASTASIOS G	33,000	$0.00
STOLL ROGER G	33,000	$0.00
BREGE LAURA A	33,000	$0.00
KOPLEWICZ HAROLD S	49,500	$0.00
LEUNG GABRIEL	33,000	$0.00
WATSON DOUGLAS G	33,000	$0.00
LEUNG GABRIEL	7,500	$1.57
LADD ROBERT B	32,680	$0.00
WATSON DOUGLAS G	32,680	$0.00
STOLL ROGER G	32,680	$0.00
LEUNG GABRIEL	32,680	$0.00
KOPLEWICZ HAROLD S	49,020	$0.00
PHILIPS LAURA A	32,680	$0.00
SIMPSON JENNIFER K	3,000	$1.49
PHILIPS LAURA A	20,000	$1.52
KOPLEWICZ HAROLD S	200	$1.50
PURPURA JOHN	5,000	$1.49
HOBBS EAMONN P	7,000	$1.52
KOPLEWICZ HAROLD S	11,867	$1.50
KOPLEWICZ HAROLD S	54,600	$1.49
PHILIPS LAURA A	20,000	$1.51
PHILIPS LAURA A	5,000	$1.43
PHILIPS LAURA A	20,000	$1.52
WATSON DOUGLAS G	50,000	$1.51

» Full list on Insider Trading

People: Delcath Systems Inc (DCTH.PH)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: